Last updated: 2026-09-16 12:38:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Sight Sciences, Inc. (SGHT) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $8,11, with a market capitalisation of $447,87M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3,19 to $9,24. This page covers its latest market performance, valuation, price trends and company information.
$447,87M | |
$8,38 | |
$42,57 | |
$1,04 | |
$8,11 | |
-- | |
225,89K | |
-- | |
$9,24 | |
$3,19 | |
-- | |
-- |
Sight Sciences, Inc. (SGHT) is trading at $8,11 in pre-market trading as of 2026-09-16 08:11:00, up 0,01% ($0,00) from the previous close of $8,11
Pre-market trading shows how investors are pricing SGHT before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Sight Sciences, Inc. (SGHT) moved from $8,35 to $8,11, representing a decline of 2,86% ($0,24).
The stock traded between $7,70 and $8,45 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 141,93 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 81,4%
SGHT is currently trading at $8,11, placing it 81,4% of the way from its 52-week low of $3,19 to its 52-week high of $9,24. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 186 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Sight Sciences, Inc. (SGHT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.